Capricor Therapeutics, Inc. - Common Stock (CAPR)
4.1500
-0.0300 (-0.72%)
NASDAQ· Last Trade: Aug 7th, 12:34 PM EDT
Detailed Quote
| Previous Close | 4.180 |
|---|---|
| Open | 4.160 |
| Bid | 4.150 |
| Ask | 4.160 |
| Day's Range | 4.135 - 4.700 |
| 52 Week Range | 2.960 - 40.37 |
| Volume | 1,668,239 |
| Market Cap | 189.70M |
| PE Ratio (TTM) | -2.610 |
| EPS (TTM) | -1.6 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 4,746,731 |
Chart
About Capricor Therapeutics, Inc. - Common Stock (CAPR)
Capricor Therapeutics is a clinical-stage biotechnology company focused on developing innovative cellular therapeutics to treat rare and chronic diseases. The company primarily works on harnessing the potential of stem cell-derived therapies, with a particular emphasis on cardiac and musculoskeletal conditions. Capricor aims to advance its proprietary technologies through rigorous research and development, striving to bring transformative treatment options to patients with unmet medical needs. By leveraging its expertise and pioneering spirit, Capricor seeks to make significant contributions to the field of regenerative medicine. Read More
News & Press Releases
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 7, 2026
NEW ORLEANS, Aug. 07, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 28, 2026 to file lead plaintiff applications in a securities class action lawsuit against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NasdaqGS: CAPR), if they purchased Capricor securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of California.
By SkyMedia, LLC · Via GlobeNewswire · August 7, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 6, 2026
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the “Class Period”).
By Kaplan Fox & Kilsheimer, LLP · Via GlobeNewswire · August 6, 2026
Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between December 17, 2025 and July 26, 2026. Find out if you could qualify to recover your losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
By Levi & Korsinsky, LLP · Via Business Wire · August 6, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 5, 2026
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. ("“Capricor” or the “Company”) (NASDAQ: CAPR) and reminds investors of the September 29, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
By Faruqi & Faruqi, LLP · Via Business Wire · August 5, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 5, 2026
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, both dates inclusive (the “Class Period”), have until September 28, 2026 to seek appointment as lead plaintiff of the Capicor class action lawsuit. Captioned Nkamga v. Capricor Therapeutics, Inc., No. 26-cv-04385 (S.D. Cal.), the Capricor class action lawsuit charges Capricor and certain of Capricor’s top executives with violations of the Securities Exchange Act of 1934.
By Robbins Geller Rudman & Dowd LLP · Via Business Wire · August 5, 2026
NEW YORK and NEW ORLEANS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NasdaqGS: CAPR) of a class action securities lawsuit.
By Kahn Swick & Foti, LLC · Via GlobeNewswire · August 4, 2026
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · August 4, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 4, 2026
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Capricor (CAPR) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · August 4, 2026
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) (“Capricor” or the “Company”) for potential violations of the federal securities laws.
By Lowey Dannenberg, P.C. · Via GlobeNewswire · August 4, 2026
Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming September 28, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 inclusive (the “Class Period”).
By Glancy Prongay Wolke & Rotter LLP · Via Business Wire · August 4, 2026
Law Offices of Howard G. Smith reminds investors of the upcoming September 28, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Capricor Therapeutics, Inc. ("Capricor" or the “Company”) (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”).
By Law Offices of Howard G. Smith · Via Business Wire · August 4, 2026
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) between December 17, 2025 and July 6, 2026, inclusive.
By Bernstein Liebhard LLP · Via GlobeNewswire · August 4, 2026
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the “Class Period”).
By Kaplan Fox & Kilsheimer, LLP · Via GlobeNewswire · August 4, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 3, 2026
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) common stock between December 17, 2025 and July 26, 2026, inclusive (“the Class Period”).
By Kirby McInerney LLP · Via Business Wire · August 3, 2026
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ:CAPR) and certain of the company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.
By Bleichmar Fonti & Auld LLP · Via Business Wire · August 3, 2026
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). Capricor is a biotechnology company.
By Rosen Law Firm · Via Business Wire · August 3, 2026
New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 3, 2026) - Kahn Swick & Foti, LLC ("KSF")...
Via Newsfile · August 3, 2026
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). Capricor investors have until September 28, 2026 to file a lead plaintiff motion.
By The Law Offices of Frank R. Cruz · Via Business Wire · August 3, 2026
The Law Offices of Frank R. Cruz reminds investors of the upcoming September 28, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Capricor Therapeutics, Inc. ("Capricor" or the Company") (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”).
By The Law Offices of Frank R. Cruz · Via Business Wire · August 3, 2026